The Week of

November 19, 2026

FDA approves first at home drug for treating sudden schizophrenic and bipolar episodes. ProMIS and Biogen advance Alzheimer's treatments.

In Psychedelics and Neuroscience...

The FDA approved IGALMI as the first prescription medication specifically authorized for treating sudden episodes of agitation at home in adults with schizophrenia, schizoaffective disorder, or bipolar I or II disorder.

The medication, also known as dexmedetomidine, comes as a thin film placed under the tongue or between the lower lip and gum. It is designed to calm agitation without requiring an injection. The drug was previously approved for use under medical supervision. The latest FDA decision expands that approval to home treatment. Here’s more: https://jlsfund.substack.com/p/fda-approves-first-at-home-treatment

ProMIS Neurosciences signed an agreement with Ossianix to license technology that could help Alzheimer's drugs reach the brain more effectively.

The technology, called TXP1, is designed to carry medications across the protective barrier that prevents many drugs from entering the brain. In early laboratory and animal studies, TXP1 increased delivery of an experimental antibody to the brain by more than 65 times.

ProMIS plans to combine the technology with its experimental Alzheimer's treatment, PMN310. It also has options to use TXP1 in future treatments for Parkinson's disease and ALS. Check it out: https://jlsfund.substack.com/p/new-technology-could-deliver-65-times

Biogen reported encouraging results for an experimental Alzheimer's drug that slowed cognitive and functional decline by 38% after two years.

The drug, called diranersen, targets tau, a protein associated with the brain damage caused by Alzheimer's disease.

In a Phase 2 study involving 416 patients with early Alzheimer's, those receiving treatment twice a year showed 38% less decline on a standard measure of disease severity, compared with 26% after 18 months. Researchers also reported a 54% slowing of decline on a separate test measuring memory and thinking abilities. Here’s more: https://jlsfund.substack.com/p/biogen-reports-encouraging-two-year

Did You Know?

Did you know Omega-3 DHA could potentially ease autism behaviors by calming inflammation?

This omega-3 fatty acid, commonly found in fish oil, may help researchers better understand the connection between brain inflammation and autism-related behaviors.

Researchers from Chongqing Medical University found that DHA improved social interaction and reduced repetitive behaviors and signs of anxiety in rats displaying autism-like behaviors. The researchers also found that DHA reduced inflammation in the brain and increased the activity of natural defenses that protect brain cells from damage.

Of course, this was an animal study, not a human clinical trial. There's no evidence from these findings that taking fish oil supplements treats autism in people.

Still, the research could help scientists understand how inflammation influences brain development and whether DHA might eventually have a role in supporting certain neurological conditions. Check it out: https://onlinelibrary.wiley.com/doi/10.1002/pdi3.91

Read More Updates